HHS to Review Medicaid Drug Rebate Data

The Department of Health and Human Services will conduct three reviews of data from the Medicaid Drug Rebate Program to examine the Centers for Medicare & Medicaid Services’ oversight.

The HHS’ Office of the Inspector General will review: Medicaid data on drug classifications and payments for FDA-approved drugs as well as reasonable assumptions made by manufacturers reporting data for the rebate program.

The move comes after CMS indicated that Mylan misclassified its epinephrine auto-injector, the EpiPen, for the drug rebate program, costing the government millions.